FDA approves
TherapeuticsMD's menopause drug
Send a link to a friend
[October 29, 2018]
(Reuters) - The U.S. Food and Drug
Administration (FDA) approved TherapeuticsMD's oral hormone therapy for
menopause symptoms such as hot flashes, sleep disturbances and night
sweats, the company said on Monday.
|
The regulatory nod is the third in five months for the drugmaker,
which received approvals for a birth control device and another
hormone therapy for menopause symptoms.
The therapy, Bijuva, is an oral softgel capsule containing a
combination of artificial hormones chemically identical to human
female sex hormones estradiol and progesterone.
TherapeuticsMD expects Bijuva to be available in the United States
in the second quarter of 2019.
About 43 million American women are of the menopausal age of between
45 and 64, according to the U.S. Census Bureau. Some 80 percent of
all menopausal women experience symptoms like hot flashes and night
sweats, the drugmaker said.
[to top of second column] |
The therapy, considered a potential blockbuster by analysts, is
expected to rake in peak U.S. sales of more than $900 million by
2027, with an estimated net price of $100 per prescription,
brokerage Cowen & Co said this month.
With nearly 36 million annual prescriptions, the current market size
for combination hormone therapies such as Bijuva could be as high as
$2 billion, the brokerage said.
Bijuva carries a boxed warning for cardiovascular disorders, breast
cancer, endometrial cancer and probable dementia.
(Reporting by Manogna Maddipatla in Bengaluru; Editing by Sai Sachin
Ravikumar)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |